Junlong Wu

1.7k total citations · 1 hit paper
66 papers, 1.1k citations indexed

About

Junlong Wu is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Surgery. According to data from OpenAlex, Junlong Wu has authored 66 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Pulmonary and Respiratory Medicine, 23 papers in Molecular Biology and 18 papers in Surgery. Recurrent topics in Junlong Wu's work include Prostate Cancer Treatment and Research (18 papers), Renal cell carcinoma treatment (11 papers) and Prostate Cancer Diagnosis and Treatment (8 papers). Junlong Wu is often cited by papers focused on Prostate Cancer Treatment and Research (18 papers), Renal cell carcinoma treatment (11 papers) and Prostate Cancer Diagnosis and Treatment (8 papers). Junlong Wu collaborates with scholars based in China, United States and Spain. Junlong Wu's co-authors include Yao Zhu, Chaoqing Yuan, Wei Yu, Sifeng Liu, Dingwei Ye, Jian Pan, Dingwei Ye, Bo Dai, Stephen J. Freedland and Weijie Gu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Junlong Wu

61 papers receiving 1.1k citations

Hit Papers

Epidemiology and genomics of prostate cancer in Asian men 2021 2026 2022 2024 2021 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Epidemiology and genomics of prostate cancer in Asian men
    2021 174 citations Yao Zhu, Wei Yu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Junlong Wu China 19 455 360 272 234 196 66 1.1k
Guangyu Luo China 20 338 0.7× 277 0.8× 310 1.1× 106 0.5× 289 1.5× 56 1.2k
Christina Plank Austria 25 390 0.9× 480 1.3× 382 1.4× 483 2.1× 508 2.6× 69 2.3k
Minhua Ye China 19 218 0.5× 644 1.8× 80 0.3× 448 1.9× 133 0.7× 73 1.2k
Yuchen Sun China 18 122 0.3× 537 1.5× 256 0.9× 334 1.4× 55 0.3× 72 1.1k
Likun Chen China 21 605 1.3× 484 1.3× 815 3.0× 297 1.3× 162 0.8× 86 1.5k
A Mulder Netherlands 20 539 1.2× 318 0.9× 522 1.9× 110 0.5× 623 3.2× 42 2.0k
Wencheng Zhao China 17 184 0.4× 192 0.5× 261 1.0× 109 0.5× 46 0.2× 48 702
Andrea De Giglio Italy 22 650 1.4× 266 0.7× 1.1k 3.9× 152 0.6× 123 0.6× 74 1.5k

Countries citing papers authored by Junlong Wu

Since Specialization
Citations

This map shows the geographic impact of Junlong Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junlong Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junlong Wu more than expected).

Fields of papers citing papers by Junlong Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Junlong Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junlong Wu. The network helps show where Junlong Wu may publish in the future.

Co-authorship network of co-authors of Junlong Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Junlong Wu. A scholar is included among the top collaborators of Junlong Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Junlong Wu. Junlong Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yu, Wei, Hualei Gan, Xiaomeng Li, et al.. (2025). Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study. Cell Reports Medicine. 6(3). 102018–102018. 3 indexed citations
2.
Jin, Shengming, et al.. (2025). Comprehensive analysis of the LINC01122/TPD52 axis as a predictive biomarker in prostate adenocarcinoma. Scientific Reports. 15(1). 16122–16122.
3.
Pan, Jian, Junlong Wu, Bin Zhu, et al.. (2024). Interlesional response heterogeneity is associated with the prognosis of abiraterone treatment in metastatic castration-resistant prostate cancer. Med. 5(12). 1475–1484.e3. 5 indexed citations
4.
5.
Wu, Junlong, Jian Pan, Xiaomeng Li, et al.. (2023). Heterogeneity of Radiological Progression Patterns and Association with Outcomes in Patients with Metastatic Prostate Cancer. European Urology Oncology. 7(4). 897–905. 1 indexed citations
6.
Yu, Wei, Jian Pan, Shengming Jin, et al.. (2023). Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity. Molecular Oncology. 17(10). 2183–2199. 6 indexed citations
7.
8.
Wu, Junlong, et al.. (2023). A novel necroptosis-associated miRNA signature predicting prognosis of endometrial cancer and correlated with immune infiltration. Taiwanese Journal of Obstetrics and Gynecology. 62(2). 291–298. 4 indexed citations
9.
Wang, Hongkai, Wei Yu, Jian Pan, et al.. (2022). Fat Attenuation Index of Renal Cell Carcinoma Reveals Biological Characteristics and Survival Outcome. Frontiers in Oncology. 12. 786981–786981. 3 indexed citations
10.
Yu, Wei, Hao Zeng, Yonghong Li, et al.. (2022). Prevalence of mismatch repair genes mutations and clinical activity of PD-1 therapy in Chinese prostate cancer patients. Cancer Immunology Immunotherapy. 72(6). 1541–1551. 11 indexed citations
11.
Wu, Junlong, Meilin Wang, Haitao Chen, et al.. (2020). The Rare Variant rs35356162 in UHRF1BP1 Increases Bladder Cancer Risk in Han Chinese Population. Frontiers in Oncology. 10. 134–134. 7 indexed citations
12.
Wang, Jun, Mierxiati Abudurexiti, Shengming Jin, et al.. (2020). Prognosis of Patients With Testicular Carcinoma Is Dependent on Metastatic Site. Frontiers in Oncology. 9. 1495–1495. 15 indexed citations
13.
Jin, Shengming, Junjie Wang, Junlong Wu, et al.. (2020). Prognostic Value of Local Treatment in Prostate Cancer Patients With Different Metastatic Sites: A Population Based Retrospective Study. Frontiers in Oncology. 10. 527952–527952. 4 indexed citations
14.
Cao, Dalong, Zihao Qi, Yangyang Pang, et al.. (2019). Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer. Cancer Research. 79(10). 2604–2618. 102 indexed citations
15.
Yu, Wei, Junlong Wu, Weijie Gu, et al.. (2019). Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients. European Urology. 76(3). 280–283. 43 indexed citations
16.
Wu, Junlong, Shengming Jin, Weijie Gu, et al.. (2019). Construction and Validation of a 9-Gene Signature for Predicting Prognosis in Stage III Clear Cell Renal Cell Carcinoma. Frontiers in Oncology. 9. 152–152. 22 indexed citations
17.
18.
Wu, Junlong, Wenhao Xu, Wei Yu, et al.. (2018). An Integrated Score and Nomogram Combining Clinical and Immunohistochemistry Factors to Predict High ISUP Grade Clear Cell Renal Cell Carcinoma. Frontiers in Oncology. 8. 634–634. 21 indexed citations
19.
Gu, Weijie, Junlong Wu, Xiaohang Liu, et al.. (2017). Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients. Scientific Reports. 7(1). 7587–7587. 20 indexed citations
20.
Gao, Hongyu, et al.. (2016). Elevated HABP1 protein expression correlates with progression and poor survival in patients with gastric cancer. OncoTargets and Therapy. Volume 9. 6711–6718. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Guangyu Luo Breakdown of academic impact, for papers by Christina Plank Breakdown of academic impact, for papers by Minhua Ye Breakdown of academic impact, for papers by Yuchen Sun Breakdown of academic impact, for papers by Likun Chen Breakdown of academic impact, for papers by A Mulder Breakdown of academic impact, for papers by Wencheng Zhao Breakdown of academic impact, for papers by Andrea De Giglio
Rankless by CCL
2026